Real-time Estimate
Other stock markets
|
5-day change | 1st Jan Change | ||
295.60 USD | +0.28% |
|
+2.23% | +13.36% |
03:08am | Amgen Insider Sold Shares Worth $7,341,123, According to a Recent SEC Filing | MT |
Feb. 10 | Piper Sandler Adjusts Amgen Price Target to $329 From $310, Maintains Overweight Rating | MT |
Business description: Amgen Inc.
- drug sales (94.2%): drugs for treating cancer, metabolic disorders, bone diseases, renal failure, hemophilia, etc.;
- other (5.8%): primarily royalties.
The United States account for 70.3% of net sales.
Number of employees: 26,700
Sales by Activity: Amgen Inc.
Fiscal Period: December | 2019 | 2020 | 2021 | 2022 | 2023 |
---|---|---|---|---|---|
Human Therapeutics | 23.36B | 25.42B | 25.98B | 26.32B | 28.19B |
Geographical breakdown of sales: Amgen Inc.
Fiscal Period: December | 2019 | 2020 | 2021 | 2022 | 2023 |
---|---|---|---|---|---|
United States (U.S.) | 17.22B | 18.5B | 18.19B | 18.6B | 19.81B |
Rest of The World (Row) | 6.14B | 6.93B | 7.78B | 7.73B | 8.38B |
Managers: Amgen Inc.
Director | Title | Age | Since |
---|---|---|---|
Robert Bradway
CEO | Chief Executive Officer | 62 | 2012-04-30 |
Peter Griffith
DFI | Director of Finance/CFO | 66 | 2019-12-31 |
David Reese
CTO | Chief Tech/Sci/R&D Officer | 62 | 2018-07-25 |
Esteban Santos
COO | Chief Operating Officer | 57 | 2016-07-24 |
Howard Y. Chang
CTO | Chief Tech/Sci/R&D Officer | - | 2024-12-15 |
Members of the board: Amgen Inc.
Manager | Title | Age | Since |
---|---|---|---|
Robert Bradway
CHM | Chairman | 62 | 2012-12-31 |
Tyler Jacks
BRD | Director/Board Member | 64 | 2011-12-31 |
Robert Eckert
BRD | Director/Board Member | 70 | 2002-12-31 |
Greg Garland
BRD | Director/Board Member | 67 | 2013-10-15 |
Ellen Kullman
BRD | Director/Board Member | 69 | 2016-10-13 |
Charles Holley
BRD | Director/Board Member | 68 | 2017-02-02 |
Wanda Austin
BRD | Director/Board Member | 70 | 2017-10-23 |
Brian Druker
BRD | Director/Board Member | 69 | 2018-05-22 |
Amy Miles
BRD | Director/Board Member | 58 | 2020-07-22 |
Omar Ishrak
BRD | Director/Board Member | 69 | 2021-07-29 |
Holdings: Amgen Inc.
Name | Equities | % | Valuation |
---|---|---|---|
BEIGENE, LTD. 19.39% | 246,269,426 | 19.39% | 4,368,597,975 $ |
NEUMORA THERAPEUTICS, INC. 21.89% | 35,368,653 | 21.89% | 68,261,500 $ |
VIGIL NEUROSCIENCE, INC. 7.84% | 3,206,281 | 7.84% | 7,630,949 $ |
Company details: Amgen Inc.

Group companies: Amgen Inc.
Name | Category and Sector |
---|---|
Amgen Manufacturing Ltd. (Bermuda)
| |
Amgen Technology Ltd.
![]() Amgen Technology Ltd. BiotechnologyHealth Technology Part of Amgen, Inc., Amgen Technology Ltd. develops, manufactures and markets human therapeutic products based on cellular biology. The company is located in Bermuda. |
Biotechnology
|
Amgen NV
![]() Amgen NV Pharmaceuticals: MajorHealth Technology Part of Amgen, Inc., Amgen NV is a pharmaceutical company based in Diegem, Belgium. The Belgian company is focused on developing innovative therapies to address serious illnesses and improve the lives of patients. Amgen is committed to advancing scientific research and delivering high-quality medicines to patients worldwide. The CEO of the company is Gabor Sztaniszlav. |
Pharmaceuticals: Major
|
Amgen Global Finance BV
![]() Amgen Global Finance BV MiscellaneousMiscellaneous Part of Amgen, Inc., Amgen Global Finance BV functions as an investment holding Dutch company. The company is based in Breda, Netherlands. |
Miscellaneous
|
Other Pharmaceuticals
Change | 5d. change | 1-year change | 3-years change | Capi.($) | ||
---|---|---|---|---|---|---|
-0.14% | +1.47% | -0.40% | +28.51% | 158B | ||
-0.13% | +4.84% | +17.47% | +267.39% | 782B | ||
-2.47% | +1.28% | -27.74% | +83.27% | 378B | ||
+1.23% | +1.76% | -1.05% | -6.87% | 371B | ||
+0.31% | +0.35% | +10.13% | +34.22% | 336B | ||
-0.83% | +0.77% | +26.68% | -17.36% | 256B | ||
-0.80% | +5.39% | +22.35% | +36.59% | 225B | ||
+1.13% | +2.56% | +11.82% | +22.90% | 210B | ||
-1.18% | -1.11% | -7.51% | -49.62% | 147B | ||
-0.15% | +0.93% | +20.41% | +10.46% | 134B | ||
Average | -0.29% | +1.97% | +7.22% | +40.95% | 299.79B | |
Weighted average by Cap. | -0.27% | +3.25% | +7.38% | +85.68% |
Sector

Quarterly revenue - Rate of surprise
- Stock Market
- Equities
- AMGN Stock
- Company Amgen Inc.